B+
Bull case
0%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
GRFS
GrifolsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$7.80
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-17
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+51.3
Score
AI commentary
Company disclosures support operating progress and a dated clinical readout, but the packet has sparse recent news, no usable social coverage and no verified analyst revisions or post-release price reaction. The sentiment metrics shown as zero are unavailable placeholders, not measured neutral readings. The deterministic prior signals very low evidence quality (0.08) and high uncertainty (0.906), warranting a monitoring stance.
RankAlpha Sentiment Codex - 2026-10-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventSPARTA Phase 3 topline readoutHigh impact
Grifols expects topline results by year-end 2026 after completing follow-up for all 345 participants. The Prolastin-C study tests whether treatment slows lung-tissue loss in alpha-1 antitrypsin deficiency; efficacy remains unproven. [#PR-2026-08-10] Grifols announcement
2026-12-31catalystCash-flow and leverage follow-throughMedium impact
H1 free cash flow before M&A improved to €91 million and leverage stood at 4.2x. Grifols reiterated 2026 guidance and expects continued immunoglobulin strength and operating improvements in H2; delivery, rather than the reiteration alone, is the test. [#IR-2026-07-28] Grifols H1 results
2027-10-17catalystImmunoglobulin label-expansion trialsMedium impact
First patients were dosed in the SIGMA and XPERT Phase 3 trials, designed to support potential U.S. label expansions for GAMUNEX-C and XEMBIFY. No readout date or approval is established in the checked announcement. [#PR-2026-07-16] Grifols announcement
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-17 • Updated nightlySource: Internal modelMethodology